Continues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancersBOCA RATON, Fla., Sept. 25, 2024…
Elixirgen Therapeutics is currently enrolling patients in its Phase 1/2 trial evaluating EXG-34217 in patients with telomere biology disorders at…
DOYLESTOWN, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical…
– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and…
JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today…
BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice…
Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their geneticsSUNNYVALE, Calif., Sept. 25,…
BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed…
Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE)…
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent…